flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 ๐ธ๐ช #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Kidney Outcomes With Glucagon-Like Peptide-1
Pay in 4 interest-free payments of $6.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6





























